CryoLife, Inc. (CRY): Price and Financial Metrics
CRY Price/Volume Stats
|Current price||$17.88||52-week high||$32.34|
|Prev. close||$17.63||52-week low||$16.95|
|Day high||$18.22||Avg. volume||198,221|
|50-day MA||$19.29||Dividend yield||N/A|
|200-day MA||$24.09||Market Cap||703.22M|
CRY Stock Price Chart Interactive Chart >
CryoLife, Inc. (CRY) Company Bio
CryoLife Inc. engages in the manufacturing, processing, and distribution of implantable living tissues and medical devices used in cardiac and vascular surgical procedures. The company was founded in 1984 and is based in Kennesaw, Georgia.
CRY Latest News Stream
|Loading, please wait...|
CRY Latest Social Stream
View Full CRY Social Stream
Latest CRY News From Around the Web
Below are the latest news stories about Cryolife Inc that investors may wish to consider to help them evaluate CRY as an investment opportunity.
CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it was renaming and rebranding itself to Artivion, Inc., effective immediately. Derived from the words "aorta", "innovation", and "vision", the company's new name and brand reflect its evolution to focus on providing innovative technologies to surgeons who treat patients with aortic disease. In conjunction with these changes, effective January 24, 2022, the company will also
The following slide deck was published by CryoLife, Inc. in conjunction with this event....
It is hard to get excited after looking at CryoLife's (NYSE:CRY) recent performance, when its stock has declined 13...
CryoLife to Participate in the Canaccord Genuity Virtual MedTech, Diagnostics, and Digital Health & Services Forum
CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that members of management will host one-on-one meetings at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital Health & Services Forum on Thursday, November 18, 2021. Due to the format of this event no webcast will be available.
The mean of analysts' price targets for CryoLife (CRY) points to a 50.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CRY Price Returns